159 related articles for article (PubMed ID: 29757894)
1. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
Zimmermann H; Babel N; Dierickx D; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Bachy E; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S; Trappe RU
Transplantation; 2018 Nov; 102(11):1914-1923. PubMed ID: 29757894
[TBL] [Abstract][Full Text] [Related]
2. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
3. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
4. Risk-adapted Treatment for Severe B-Lineage Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation in Children.
Giraldi E; Provenzi M; Conter V; Colledan M; Bolognini S; Foglia C; Sebastiani R; Fiocchi R; Gianatti A; DʼAntiga L; Rambaldi A
Transplantation; 2016 Feb; 100(2):437-45. PubMed ID: 26270449
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
[TBL] [Abstract][Full Text] [Related]
6. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
[TBL] [Abstract][Full Text] [Related]
7. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
8. Posttransplant lymphoproliferative disorder.
Everly MJ; Bloom RD; Tsai DE; Trofe J
Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
[TBL] [Abstract][Full Text] [Related]
9. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.
Choquet S; Trappe R; Leblond V; Jäger U; Davi F; Oertel S
Haematologica; 2007 Feb; 92(2):273-4. PubMed ID: 17296588
[TBL] [Abstract][Full Text] [Related]
10. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
[TBL] [Abstract][Full Text] [Related]
11. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P
Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
[TBL] [Abstract][Full Text] [Related]
12. EBV and posttransplantation lymphoproliferative disease: what to do?
Zimmermann H; Trappe RU
Hematology Am Soc Hematol Educ Program; 2013; 2013():95-102. PubMed ID: 24319169
[TBL] [Abstract][Full Text] [Related]
13. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases.
Patel H; Vogl DT; Aqui N; Shaked A; Olthoff K; Markmann J; Reddy R; Stadtmauer EA; Schuster S; Tsai DE
Leuk Lymphoma; 2007 May; 48(5):885-91. PubMed ID: 17487731
[TBL] [Abstract][Full Text] [Related]
14. Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.
Podoltsev N; Zhang B; Yao X; Bustillo I; Deng Y; Cooper DL
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):716-20. PubMed ID: 24035715
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
[TBL] [Abstract][Full Text] [Related]
16. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
[TBL] [Abstract][Full Text] [Related]
17. Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression.
Trappe R; Hinrichs C; Appel U; Babel N; Reinke P; Neumayer HH; Budde K; Dreyling M; Dührsen U; Kliem V; Schüttrumpf S; Hauser IA; Mergenthaler HG; Schlattmann P; Anagnostopoulos I; Doerken B; Riess H
Am J Transplant; 2009 Oct; 9(10):2331-7. PubMed ID: 19663889
[TBL] [Abstract][Full Text] [Related]
18. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
[TBL] [Abstract][Full Text] [Related]
19. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival.
Serre JE; Michonneau D; Bachy E; Noël LH; Dubois V; Suberbielle C; Kreis H; Legendre C; Mamzer-Bruneel MF; Morelon E; Thaunat O
Kidney Int; 2014 Jan; 85(1):182-90. PubMed ID: 23802193
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants.
Davis CL; Wood BL; Sabath DE; Joseph JS; Stehman-Breen C; Broudy VC
Transplantation; 1998 Dec; 66(12):1770-9. PubMed ID: 9884275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]